Shares of Progyny, Inc. (NASDAQ:PGNY – Get Free Report) have earned a consensus rating of “Moderate Buy” from the fifteen ratings firms that are presently covering the firm, MarketBeat reports. Four research analysts have rated the stock with a hold recommendation and eleven have issued a buy recommendation on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $35.33.
Several research firms have weighed in on PGNY. Barclays decreased their price target on shares of Progyny from $34.00 to $30.00 and set an “equal weight” rating on the stock in a research report on Wednesday, August 12th. Zacks Research downgraded shares of Progyny from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 19th. Citizens Jmp upped their price objective on Progyny from $33.00 to $38.00 and gave the stock a “market outperform” rating in a research note on Thursday, November 5th. BTIG Research upped their price objective on Progyny from $30.00 to $40.00 and gave the stock a “buy” rating in a research note on Friday, July 24th. Finally, Wall Street Zen raised Progyny from a “buy” rating to a “strong-buy” rating in a report on Sunday, November 8th.
Check Out Our Latest Report on Progyny
Progyny Stock Down 1.1%
Shares of Progyny stock traded down $0.40 during trading hours on Tuesday, reaching $36.18. 869,008 shares of the stock traded hands, compared to its average volume of 1,062,968. The company has a 50 day moving average price of $28.48 and a 200 day moving average price of $24.87. The firm has a market capitalization of $2.66 billion, a price-to-earnings ratio of 33.19, a P/E/G ratio of 1.70 and a beta of 0.97. Progyny has a one year low of $16.10 and a one year high of $37.15.
Progyny (NASDAQ:PGNY – Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.31 by $0.21. The firm had revenue of $341.25 million during the quarter, compared to analyst estimates of $340.76 million. Progyny had a net margin of 6.80% and a return on equity of 19.82%. The business’s revenue for the quarter was up 8.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.15 EPS. Sell-side analysts anticipate that Progyny will post 1.41 earnings per share for the current year.
Insider Buying and Selling at Progyny
In other Progyny news, CEO Peter Anevski sold 236,630 shares of the company’s stock in a transaction dated Tuesday, November 10th. The stock was sold at an average price of $35.84, for a total value of $8,480,819.20. Following the completion of the sale, the chief executive officer owned 710,972 shares in the company, valued at $25,481,236.48. This represents a 24.97% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Geoffrey Clapp sold 774 shares of the company’s stock in a transaction dated Wednesday, November 11th. The stock was sold at an average price of $36.41, for a total value of $28,181.34. Following the completion of the sale, the insider owned 58,235 shares of the company’s stock, valued at approximately $2,120,336.35. The trade was a 1.31% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 630,072 shares of company stock valued at $22,363,084 in the last ninety days. 9.90% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Progyny
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. AWM Investment Company Inc. raised its position in shares of Progyny by 6.8% during the 3rd quarter. AWM Investment Company Inc. now owns 235,000 shares of the company’s stock valued at $5,920,000 after purchasing an additional 15,000 shares during the period. Kovack Advisors Inc. purchased a new stake in Progyny in the 3rd quarter worth $72,000. First Trust Advisors LP increased its stake in Progyny by 302.2% in the 3rd quarter. First Trust Advisors LP now owns 425,903 shares of the company’s stock worth $10,728,000 after buying an additional 320,010 shares in the last quarter. Public Sector Pension Investment Board increased its stake in Progyny by 3.5% in the 3rd quarter. Public Sector Pension Investment Board now owns 322,105 shares of the company’s stock worth $8,785,000 after buying an additional 10,918 shares in the last quarter. Finally, Edgestream Partners L.P. bought a new stake in Progyny during the third quarter valued at about $1,306,000. Institutional investors own 94.93% of the company’s stock.
Progyny Company Profile
Progyny, Inc. provides fertility and family-building benefits to employers and their employees. Its services are designed to help members navigate care options, access fertility specialists and receive support throughout treatment. The company’s offerings include coverage for treatments such as in vitro fertilization and egg freezing, along with fertility medications through its pharmacy benefit. Progyny also supports other family-building paths, including adoption and surrogacy, depending on the plan selected by an employer.
See Also
- Five stocks we like better than Progyny
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.
